Rnable
RNAble is a preclinical biotechnology company developing a potent small-molecule inhibitor targeting FTO, a key driver of oncogenic RNA biology. Mechanistic studies have led to the identification of a specific biomarker that predicts pan-cancer sensitivity to the inhibitor across both hematological and solid malignancies. Key highlights of RNAble's lead candidate: • Demonstrates strong in vivo efficacy and superior antitumor activity compared to standard-of-care therapies in AML models. • Shows promising efficacy in preclinical models of biomarker-selected solid tumors. • Features a novel, validated mechanism of action that induces cancer cell death via RNA-mediated mitotic catastrophe followed by apoptosis, with potential to overcome resistance to current therapies. • Exhibits strong oral bioavailability and a favorable safety profile. • Expected IND submission in 2026.
7-day free trial · no credit card
Verified contacts
5
available on Kipplo
LinkedIn employees
4
1 to 10 range
Open roles
—
no listings
Distinct roles
3
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 5 verified contacts at Rnable
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
5 contacts with verified email or phone · masked until revealed.
- RE
Reut Eshel
Senior Scientist · Science
EmailPhone - AM
Amir Mor
Chief Scientific Officer and Co-founder · Science
EmailPhone
Showing 2 of 5 verified contacts
Top roles at Rnable
3 distinct titles indexed · top 3 shown.
- 3senior scientist
- 1chief scientific officer and co-founder
- 1research assistant
Sign up to unlock all 5 contacts at Rnable
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 5 verified contacts at Rnable
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.